Trial · NCT02429375
Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT02429375, Phase 1, Phase 2, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2022-05-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma. Trials, record NCT02429375. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02429375
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma
- NCT number
- NCT02429375
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 7 participants, actual
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- Hodgkin Lymphoma
- Interventions
- Mocetinostat Plus Brentuximab Vedotin
- First posted
- 2015-04-29
- Last updated
- 2022-05-12
- Results first posted
- 2022-05-12
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum Tolerated Dose (MTD) | 1 year | For this objective the standard 3+3 dose-escalation scheme will be used. Patients will be accrued to the study in cohorts of 3 (starting with dose level 1). For any given dose an initial cohort of 3 patients will be treated at that dose. The dose level will be escalated if none of the 3 patients exhibits any DLT |
| Secondary | Overall Response Rate (ORR) | 1 year | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Maximum Tolerated Dose (MTD) | 1 year | Data were not collected | ||
| SECONDARY | Overall Response Rate (ORR) | 1 year | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate (ORR) | Dose Level 1: 50mg Mocetinostat | Progression of Disease | 2 | Participants | |
| Overall Response Rate (ORR) | Dose Level 2: 70mg Mocetinostat | Progression of Disease | 0 | Participants | |
| Overall Response Rate (ORR) | Dose Level 3: 90mg Mocetinostat | Progression of Disease | 1 | Participants | |
| Overall Response Rate (ORR) | Dose Level 1: 50mg Mocetinostat | Partial Response | 0 | Participants | |
| Overall Response Rate (ORR) | Dose Level 2: 70mg Mocetinostat | Partial Response | 2 | Participants | |
| Overall Response Rate (ORR) | Dose Level 3: 90mg Mocetinostat | Partial Response | 0 | Participants | |
| Overall Response Rate (ORR) | Dose Level 1: 50mg Mocetinostat | Stable Disease | 0 | Participants | |
| Overall Response Rate (ORR) | Dose Level 2: 70mg Mocetinostat | Stable Disease | 1 | Participants | |
| Overall Response Rate (ORR) | Dose Level 3: 90mg Mocetinostat | Stable Disease | 0 | Participants | |
| Overall Response Rate (ORR) | Dose Level 1: 50mg Mocetinostat | NA - Patient Withdrawal of Consent | 1 | Participants |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Dose Level 1: 50mg Mocetinostat | 3 | |
| Overall Study | STARTED | Dose Level 2: 70mg Mocetinostat | 3 | |
| Overall Study | STARTED | Dose Level 3: 90mg Mocetinostat | 1 | |
| Overall Study | COMPLETED | Dose Level 1: 50mg Mocetinostat | 3 | |
| Overall Study | COMPLETED | Dose Level 2: 70mg Mocetinostat | 3 | |
| Overall Study | COMPLETED | Dose Level 3: 90mg Mocetinostat | 1 | |
| Overall Study | NOT COMPLETED | Dose Level 1: 50mg Mocetinostat | 0 | |
| Overall Study | NOT COMPLETED | Dose Level 2: 70mg Mocetinostat | 0 | |
| Overall Study | NOT COMPLETED | Dose Level 3: 90mg Mocetinostat | 0 |
Source ClinicalTrials.gov
Adverse events87
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | White blood cell decreased | Investigations | Dose Level 1: 50mg Mocetinostat | 0 | 3 | |
| other | White blood cell decreased | Investigations | Dose Level 2: 70mg Mocetinostat | 2 | 3 | |
| other | White blood cell decreased | Investigations | Dose Level 3: 90mg Mocetinostat | 0 | 1 | |
| other | Hyperglycemia | Metabolism and nutrition disorders | Dose Level 1: 50mg Mocetinostat | 0 | 3 | |
| other | Hyperglycemia | Metabolism and nutrition disorders | Dose Level 2: 70mg Mocetinostat | 0 | 3 | |
| other | Hyperglycemia | Metabolism and nutrition disorders | Dose Level 3: 90mg Mocetinostat | 1 | 1 | |
| other | Platelet count decreased | Investigations | Dose Level 1: 50mg Mocetinostat | 0 | 3 | |
| other | Platelet count decreased | Investigations | Dose Level 2: 70mg Mocetinostat | 1 | 3 | |
| other | Platelet count decreased | Investigations | Dose Level 3: 90mg Mocetinostat | 0 | 1 | |
| other | Alanine aminotransferase increased | Investigations | Dose Level 1: 50mg Mocetinostat | 0 | 3 |
1 to 10 of 87Source ClinicalTrials.gov
See all 87 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Dose Level 1: 50mg Mocetinostat | 0 | 3 |
| Total, all-cause mortality | Dose Level 2: 70mg Mocetinostat | 0 | 3 |
| Total, all-cause mortality | Dose Level 3: 90mg Mocetinostat | 1 | 1 |
| Total, other adverse events | Dose Level 1: 50mg Mocetinostat | 3 | 3 |
| Total, other adverse events | Dose Level 2: 70mg Mocetinostat | 3 | 3 |
| Total, other adverse events | Dose Level 3: 90mg Mocetinostat | 1 | 1 |
| Total, serious adverse events | Dose Level 1: 50mg Mocetinostat | 1 | 3 |
| Total, serious adverse events | Dose Level 2: 70mg Mocetinostat | 0 | 3 |
| Total, serious adverse events | Dose Level 3: 90mg Mocetinostat | 1 | 1 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02429375
GET https://conductscience.org/api/trials/v1/NCT02429375/events?page=2